DDInter856 DDInter156
Unfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers with weights ranging from 3000 to 30,000 Da. It is a naturally occurring anticoagulant released from mast cells. It binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin (factor IIa) and factor Xa. UH is different from low molecular weight heparin (LMWH) in the following ways: the average molecular weight of LMWH is about 4.5 kDa whereas it is 15 kDa for UH; UH requires continuous infusions; activated partial prothrombin time (aPTT) monitoring is required when using UH; and UH has a higher risk of bleeding and higher risk of osteoporosis in long term use. Unfractionated hepar
Azilsartan medoxomil is a prodrug that is broken down to azilsartan, which belongs in the angiotensin-receptor blocking (ARB) drug class. It is a selective AT1 subtype angiotensin II receptor antagonist. Azilsartan medoxomil is a relatively recently-developed antihypertensive drug that was first approved by the FDA in February 2011. Many guidelines recommend the use of ARBs as first-line therapy when initiating antihypertensive therapy and indicate that the clinical efficacy of ARBs is comparable to angiotensin-converting enzyme (ACE) inhibitors that are also used as first-line treatment for hypertension. Azilsartan medoxomil is marketed under the brand name Edarbi. It is used to treat hypertension as monotherapy or in combination with other antihypertensive drugs. It is also available in a combination product with [chlorthalidone]. As hypertension is a major risk factor for cardiovascular disease, early management of hypertension has several implications on patients' survival rate and quality of life in the future. Lowering blood pressure is associated with a reduced risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Azilsartan medoxomil is thus speculated to lower mortality rates and the onset of cardiovascular disease. Although there is no clinical significance yet determined, azilsartan medoxomil may have potential off-label uses in patients with a history of myocardial infarction or heart failure.
Azilsartan medoxomil {u} (Compound) resembles {v} (Compound) Tasosartan
Azilsartan medoxomil {u} (Compound) binds {v} (Gene) AGTR1
Azilsartan medoxomil {u} (Compound) is included by {v} (Pharmacologic Class) Angiotensin 2 Type 1 Receptor Antagonists
Azilsartan medoxomil {u} (Compound) causes {v} (Side Effect) Hyperuricaemia
Azilsartan medoxomil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Azilsartan medoxomil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dapagliflozin
Azilsartan medoxomil {u} may lead to a major life threatening interaction when taken with {v} Potassium chloride
Azilsartan medoxomil {u} may lead to a major life threatening interaction when taken with {v} Potassium gluconate
Azilsartan medoxomil (Compound) resembles Tasosartan (Compound)
Azilsartan medoxomil (Compound) binds AGTR1 (Gene)
Azilsartan medoxomil (Compound) is included by Angiotensin 2 Type 1 Receptor Antagonists (Pharmacologic Class)
Azilsartan medoxomil (Compound) causes Hyperuricaemia (Side Effect)
Azilsartan medoxomil may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Azilsartan medoxomil may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin
Azilsartan medoxomil may lead to a major life threatening interaction when taken with Potassium chloride
Azilsartan medoxomil may lead to a major life threatening interaction when taken with Potassium gluconate